WO2000063675A1 - Identification d'un marqueur serique de l'endometriose - Google Patents

Identification d'un marqueur serique de l'endometriose Download PDF

Info

Publication number
WO2000063675A1
WO2000063675A1 PCT/US2000/009737 US0009737W WO0063675A1 WO 2000063675 A1 WO2000063675 A1 WO 2000063675A1 US 0009737 W US0009737 W US 0009737W WO 0063675 A1 WO0063675 A1 WO 0063675A1
Authority
WO
WIPO (PCT)
Prior art keywords
endometriosis
sample
subject
antibody
serum
Prior art date
Application number
PCT/US2000/009737
Other languages
English (en)
Inventor
Eytan Barnea
Original Assignee
Bioincept, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioincept, Inc. filed Critical Bioincept, Inc.
Priority to AU42335/00A priority Critical patent/AU4233500A/en
Publication of WO2000063675A1 publication Critical patent/WO2000063675A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70507—C2D
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/364—Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des procédés de criblage destinés au diagnostic et au pronostic de l'endométriose chez des sujets par la détection de taux élevés du facteur de l'endométriose (EF) dans le sérum et d'autres liquides biologiques du sujet. Le procédé de l'invention consiste à utiliser des échantillons de sérum dérivés du sujet ou des échantillons d'autres liquides biologiques pour déterminer l'existence et le taux de EF dans l'échantillon. Le taux de EF dans l'échantillon peut être testé, par exemple, au moyen d'un dosage de liaison lymphocytes/plaquettes. L'invention se fonde sur la découverte selon laquelle le sérum dérivé des sujets souffrant de l'endométriose contient des taux élevés d'un facteur qui augmente le taux de liaison des plaquettes aux lymphocytes. La présente invention concerne en outre des kits permettant de mettre en oeuvre les procédés de dépistage ci-décrits. Ces kits peuvent être utilisés pour dépister des taux élevés de EF chez des sujets, qui servent d'indicateur diagnostique, prédictif ou pronostique de l'endométriose. L'invention est confirmée par des exemples dans lesquels des taux élevés de EF ont été identifiés dans des échantillons de sérum dérivés des sujets souffrant de l'endométriose.
PCT/US2000/009737 1999-04-16 2000-04-12 Identification d'un marqueur serique de l'endometriose WO2000063675A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU42335/00A AU4233500A (en) 1999-04-16 2000-04-12 Identification of a serum marker for endometriosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12955799P 1999-04-16 1999-04-16
US60/129,557 1999-04-16

Publications (1)

Publication Number Publication Date
WO2000063675A1 true WO2000063675A1 (fr) 2000-10-26

Family

ID=22440570

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/009737 WO2000063675A1 (fr) 1999-04-16 2000-04-12 Identification d'un marqueur serique de l'endometriose

Country Status (2)

Country Link
AU (1) AU4233500A (fr)
WO (1) WO2000063675A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7268117B2 (en) 2003-07-11 2007-09-11 Praecis Pharmaceuticals Incorporated Compositions, kits, and methods for identification, assessment, prevention, and therapy of endometriosis
US7879562B2 (en) 2004-07-07 2011-02-01 Siemens Healthcare Diagnostics Inc. Methods of diagnosing endometriosis in human subjects using the ME-5 polypeptide
CN101334410B (zh) * 2007-06-26 2013-03-27 沙桂华 一种检测子宫内膜异位症的试剂盒
WO2017079430A1 (fr) * 2015-11-03 2017-05-11 Bioincept, Llc Peptides et méthodes de traitement de l'endométriose utilisant lesdits peptides
US11090355B2 (en) 2015-08-28 2021-08-17 Bioincept, Llc Compositions and methods for the treatment of neurodamage
US11096987B2 (en) 2015-08-28 2021-08-24 Bioincept, Llc Mutant peptides and methods of treating subjects using the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646003A (en) * 1994-03-23 1997-07-08 Barnea; Eytan R. Preimplantation factor
US5665556A (en) * 1990-03-02 1997-09-09 Brigham And Women's Hospital Complement components and binding ligands in fertility
US5843673A (en) * 1994-10-25 1998-12-01 Curators Of The University Of Missouri Method of screening for endometriosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665556A (en) * 1990-03-02 1997-09-09 Brigham And Women's Hospital Complement components and binding ligands in fertility
US5646003A (en) * 1994-03-23 1997-07-08 Barnea; Eytan R. Preimplantation factor
US5843673A (en) * 1994-10-25 1998-12-01 Curators Of The University Of Missouri Method of screening for endometriosis

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
MORTON ET. AL.: "An Early Pregnancy Factor Detected in Human Serum by the Rosette Inhibition Test", THE LANCET, 19 February 1977 (1977-02-19), pages 394 - 399, XP002929727 *
MORTON ET. AL.: "Studies of the Rosette Inhibition Test in Pregnant Mice: Evidence of Immunosuppression", PROC. R. SOC. LOND. B., vol. 193, 1976, pages 413 - 419, XP002929728 *
MURPHY ET. AL.: "Lysophosphatidyl Choline, a Chemotactic Factor for Monocytes/T-Lymphocytes is Elevated in Endometriosis", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 83, no. 6, 1998, pages 2110 - 2113, XP002929734 *
NOTHNICK ET. AL.: "Detection of a Unique 32-kd Protein in the Peritoneal Fluid of Women with Endometriosis", FERTILITY AND STERILITY, vol. 61, no. 2, February 1994 (1994-02-01), pages 288 - 293, XP002929729 *
O'NEILL ET. AL.: "Use of a Bioassay for Embryo-Derived Platelet Activating Factor as a Means of Assessing Quality and Pregnancy Potential of Human Embryos", FERTILITY AND STERILITY, vol. 47, no. 6, June 1987 (1987-06-01), pages 969 - 975, XP002929730 *
PILLAI ET. AL.: "Antibodies to Endometrial Transferrin and Alpha 2-Heremans Schmidt (HS) Glycoprotein in Patients with Endometriosis", AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, vol. 35, 1996, pages 483 - 494, XP002929731 *
SHARPE-TIMMS ET. AL.: "Endometriotic Lesions synthesize and Secrete a Haptoglobin-Like protein", BIOLOGY OF REPRODUCTION, vol. 58, 1998, pages 988 - 994, XP002929733 *
SMART ET. AL.: "Rosette Inhibition Test: Assay for Detection Early Pregnancy Factor", PERINATOLOGY PRESS., 1985, pages 105 - 116, XP002929732 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7268117B2 (en) 2003-07-11 2007-09-11 Praecis Pharmaceuticals Incorporated Compositions, kits, and methods for identification, assessment, prevention, and therapy of endometriosis
US7879562B2 (en) 2004-07-07 2011-02-01 Siemens Healthcare Diagnostics Inc. Methods of diagnosing endometriosis in human subjects using the ME-5 polypeptide
US7981626B2 (en) 2004-07-07 2011-07-19 Siemens Healthcare Diagnostics Inc. Method of detecting endometriosis in human subjects using SEQ ID No. 9 or an epitope thereof
US8030007B2 (en) 2004-07-07 2011-10-04 Siemens Healthcare Diagnostics Inc. Method for the detection of endometriosis using an ME-2 antigen
CN101334410B (zh) * 2007-06-26 2013-03-27 沙桂华 一种检测子宫内膜异位症的试剂盒
US11090355B2 (en) 2015-08-28 2021-08-17 Bioincept, Llc Compositions and methods for the treatment of neurodamage
US11096987B2 (en) 2015-08-28 2021-08-24 Bioincept, Llc Mutant peptides and methods of treating subjects using the same
WO2017079430A1 (fr) * 2015-11-03 2017-05-11 Bioincept, Llc Peptides et méthodes de traitement de l'endométriose utilisant lesdits peptides
AU2016349358B2 (en) * 2015-11-03 2019-12-05 Bioincept, Llc Peptides and methods of treating endometriosis using the same

Also Published As

Publication number Publication date
AU4233500A (en) 2000-11-02

Similar Documents

Publication Publication Date Title
US11156613B2 (en) Detection of cancer by elevated levels of bcl-2
Poole et al. The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases
Kuwana et al. Enzyme‐linked immunosorbent assay for detection of anti–RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis
O'Connor et al. Development of highly sensitive immunoassays to measure human chorionic gonadotropin, its β-subunit, and β core fragment in the urine: application to malignancies
US20090197342A1 (en) Marker for Inflammatory Conditions
EP2965088B1 (fr) Marqueur pronostique pour déterminer le risque de prééclampsie précoce
CA1305408C (fr) Methode de diagnostic de la maladie de lyme
US4447545A (en) Bladder cancer detection
JP3943575B2 (ja) 切迫分娩についての危険にある女性における膜の破裂を決定するための検定方法
US20180238890A1 (en) Methods and materials for detection, diagnosis and management of ovarian cancer
JP4820003B2 (ja) 癌の血清マーカーとしてのｓ１００タンパク質および自己抗体
WO2000063675A1 (fr) Identification d'un marqueur serique de l'endometriose
Selvarajan et al. The HercepTest and routine C-erbB2 immunohistochemistry in breast cancer: any difference?
Cappy et al. Falsely elevated serum antimüllerian hormone level in a context of heterophilic interference
CN113287013A (zh) 溃疡性大肠炎以及原发性硬化性胆管炎的检查方法
Gupta et al. Measurement of immunoreactive myelin basic protein peptide (45–89) in cerebrospinal fluid
IE921132A1 (en) Endometrial antigen, composition, test kit and method for¹endometrial antibody determination
EP1120651A1 (fr) Technique et reactif utilises pour l'analyse de la melanotransferrine associee a l'arthrite
Vuori et al. The use of myoglobin/carbonic anhydrase III ratio as a marker for myocardial damage in patients with renal failure
WO1993024836A1 (fr) Methode de depistage de femmes presentant un risque eleve d'accouchement avant terme
Saji et al. Clinical evaluation of the enzyme-linked immunosorbent assay (ELISA) kit for antisperm antibodies
WO2000063231A1 (fr) Facteur de liaison lymphocytes/plaquettes utilise comme marqueur serique du cancer
WO2024085195A1 (fr) Méthode d'examen d'une entérite liée à un événement indésirable d'origine immunitaire
KR101652894B1 (ko) 대장암에 대한 신규 바이오마커 및 그의 용도
JP2003121444A5 (fr)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA IL JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 09958498

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP